Research

The Scorecard
MSTR
The Scorecard: 1 Month Update: MSTR Sell — Correct so far
Nov 1, 2026
Revisiting our Sell call on MSTR: entry $160.50, latest $130.51, -18.7%.
Read note
Equity Research
ENPH
Enphase Energy Stock Analysis: Buy or Sell? Valuation, Revenue Decline, Cash & Margins
Oct 31, 2026
Enphase Energy (ENPH) carries a STRONG SELL rating as shrinking revenue and a still-rich valuation outweigh its strong cash balance. The business has a solid platform, but the top line is down sharply and the recovery has yet to show up in results.
Read note
Equity Research
WMB
Williams Companies Stock Analysis: Buy or Sell? Valuation & Leverage
Oct 30, 2026
Williams Companies (WMB) is rated Hold because its fee-based pipeline franchise is durable, but the stock already trades at a rich multiple. Negative free cash flow and 4.35x net debt/EBITDA keep the leverage risk front and center.
Read note
Equity Research
SM
SM Energy Stock Analysis: Buy or Sell? Valuation, Leverage & FCF
Oct 30, 2026
SM Energy (SM) is a Buy, backed by $1.5B in trailing free cash flow and a 15.5% FCF yield. The stock looks undervalued at 5.1x EV/EBITDA, but leverage and tight liquidity remain the key risks.
Read note
Equity Research
FORM
FormFactor Stock Analysis: Buy or Sell? AI Demand, Customer Concentration & Valuation
Oct 30, 2026
FormFactor (FORM) is rated Hold as AI and HBM demand are driving strong growth, but the stock already discounts much of the upside. Rich valuation and customer concentration keep the risk-reward balanced.
Read note
Equity Research
NXPI
NXP Semiconductors Stock Analysis: Buy or Sell? Valuation & Leverage
Oct 30, 2026
NXP Semiconductors (NXPI) is rated Hold as solid cash generation offsets a valuation that already prices in recovery. Free cash flow is strong, but 11B of debt and 1.3x net debt/EBITDA leave less room for a downturn.
Read note
Weekly Performance Update
BMNR, BW, CIFR, FLNC, NLST, SDGR
Weekly Performance Update — October 30, 2026
Oct 30, 2026
Across 219 articles, our hit rate this run is 73.7% and our average signal return is 11.9%, so the overall record is still solid. Among the tiers with meaningful sample sizes, Sell is performing best on both accuracy and average signal return, while
Read note
SEC What Changed
NPLY
Naploy (NPLY) 2026 10-K Analysis: MD&A Changes
Oct 30, 2026
Naploy (NPLY) 2026 10-K analysis comparing the 30 October 2026 filing with its prior-year 10-K, highlighting the MD&A section’s biggest changes.
Read note
Equity Research
VKTX
Viking Therapeutics Stock Analysis: Buy or Sell? Cash Burn & Valuation
Oct 29, 2026
Viking Therapeutics (VKTX) is rated STRONG SELL because heavy cash burn is consuming a large cash balance while the stock still trades at a rich valuation. Phase 3 obesity progress remains the key swing factor, but the current risk/reward looks unfavorable.
Read note
SEC What Changed
EPAC, HMMR, IIIN, PURE, RFL, RYES
Rafael Holdings (RFL) 10-K: MD&A Changes Lead 29 October 2026 Filing Roundup
Oct 29, 2026
Rafael Holdings (RFL)’s MD&A section changed the most among 6 companies that filed 10-Ks on 29 October 2026, each compared against its prior-year filing.
Read note

Waitlist

Join the lf0 premium research waitlist.

More detailed equity research, scorecards, and performance analysis are coming. Add your email to be first in line.

Join the Waitlist